News

ViroPharma has posted a net income of $38.34m for the third quarter 2010, or $0.45 per diluted share, compared to $20.07m, or $0.24 per diluted share, for the

Prior to joining Cenergy, Thomas served as COO of Engineered Sports Technology (EST), where he was successful in building relationships with raw material manufacturers as well as upper-level

Most recently, Downey was the CEO of Ketal Biomedical. Before joining Ketal, he was the president and CEO of the US and Canadian operations of Solvay Pharmaceuticals (now

AV-203 is an ErbB3 (HER3)-targeted antibody, which belongs to a family of four proteins that also includes the epidermal growth factor receptor (EGFR) and the HER2 receptor. Laureate’s

Sangamo posted a net loss of $8.7m for the third quarter 2010, or $0.19 per diluted share, compared to net loss of $4.85m, or $0.12 per diluted share,

Vesicare OD, a muscarine receptor antagonist discovered and developed by Astellas, was approved for an additional formulation of the overactive bladder treatment with the indication of urinary frequency,

Omnicell has posted a net income of $1.28m for the third quarter 2010, or $0.04 per diluted share, compared to $854,000m, or $0.03 per diluted share, for the

PPD posted a net income of $38m for the third quarter 2010, or $0.33 per diluted share, compared to $37.67m, or $0.34 per diluted share, for the comparable

The partnership will provide integration of technologies and processes, giving biopharmaceutical companies near real-time, consistent and reliable medical imaging information to expedite their drug development programs. The integration